Clinical trial
UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants
NCT00098969 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00098969 |
|---|---|
| Title | UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants |
| Official title | Phase I Single-Dose Safety and Phamacokinetics Clinical Study of Resveratrol AKA IRB 2003-424 |
| Acronym | IRB 2004-535 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | resveratrol |
| Enrollment | 40 |
| Start date | Sep 1, 2004 |
| First posted | Dec 9, 2004 |
| Last update posted | Dec 17, 2012 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: